MAPT and Alzheimer disease: The Src family kinase inhibitor, saracatinib, targeting Fyn as a therapeutic intervention in AD, based on its activation by Aβ via cellular prion protein but also due to its known interaction with tau, uniquely linking the two key pathologies in AD.